Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00452478
Status:
TERMINATED
Last Update Posted:
2021-05-25
First Post:
2007-03-23
Brief Title:
Conversion From Standard Phosphate Binder Therapy to Fosrenol Lanthanum Carbonate in Chronic Kidney Disease Stage 5
Sponsor:
Shire
Organization:
Takeda
Study Overview
Official Title:
A Phase IV Open-Label Multi-Centre Trial Evaluating the Conversion From Standard Phosphate Binder Therapy to Fosrenol in Chronic Kidney Disease Stage 5 Patients on Haemodialysis
Status:
TERMINATED
Status Verified Date:
2021-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
This study was stopped by the sponsor based on a non-safety related corporate decision
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main aim of this research study is to see if giving Fosrenol a chewable tablet to patients on haemodialysis works as well as other treatments currently used to lower blood phosphorus levels
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006-003364-64 | EUDRACT_NUMBER | None | None |